The global market for infectious disease treatments is expected to grow from $72.5 billion in 2025 and is projected to reach $101 billion by the end of 2030, at a compound annual growth rate (CAGR) of 6.9% during the forecast period of 2025 to 2030.
The North American market for infectious disease treatments is expected to grow from $39.9 billion in 2025 and is projected to reach $54.7 billion by the end of 2030, at a CAGR of 6.5% during the forecast period of 2025 to 2030.
The European market for infectious disease treatments is expected to grow from $13.5 billion in 2025 and is projected to reach $17.7 billion by the end of 2030, at a CAGR of 5.6% during the forecast period of 2025 to 2030.
Report Scope
This report offers an analysis of the global market for infectious disease therapeutics, vaccines, and diagnostics. The infectious diseases covered in the report include human immunodeficiency virus (HIV) infection, seasonal influenza (including influenza A and B), hepatitis B, hepatitis C, respiratory syncytial virus (RSV) infection, tuberculosis (TB), herpes simplex virus (HSV) infection, malaria, rotavirus infection, and viral hemorrhagic fevers such as yellow fever, dengue, Lassa fever, Ebola fever, and Zika fever.
The report's estimates of the infectious disease market include global revenue ($ millions) for the base year of 2024, estimates for 2025, and data for the forecast period of 2026 through 2030. The report focuses on the major trends, challenges and opportunities in the market and vendor landscape. It also covers the new products, acquisitions, and collaborations related to the market. The report also analyzes environmental, social, and corporate governance (ESG) developments.
The report concludes with an analysis of the competitive landscape, which provides a ranking by market share of leading companies in the market. There is also a section of profiles of the leading companies.
Outside the scope of the report are vector/mosquito control approaches, strategies and products, drugs used for symptomatic treatment and not for the elimination of the virus from the host, and details on suppliers of generics and non-branded generics. Also excluded are markets for hospital-based diagnosis that are not carried out by kits (for example, malaria slide smear-based tests), as well as discussion of the spread of vector-borne infection (such as malaria) via blood transfusion.
Report Includes
- 53 data tables and 69 additional tables
- A review of the global market for infectious disease treatments in the healthcare and pharmaceutical industry
- Analyses of the global market trends, with sales data from 2022-2024, estimates for 2025, and projected CAGRs through 2030
- Evaluation and forecast of the overall market size in terms of dollar value terms, and corresponding market share analysis based on product type, disease type, and geographic region
- An evaluation of the market potential for infectious disease treatments, opportunities and gaps, estimating current and future demand
- Discussion of new drugs and innovations in chemical compounds, vaccines and biologicals and diagnostic kits that are recently launched or in development
- Review of key patent grants and new technologies related to innovations in infectious disease treatments
- Identification of challenges and discussion of how to overcome these to be able to reach commercialization potential, and ESG trends of the market
- Market share analysis of the key companies of the industry and coverage of their proprietary technologies, strategic alliances, and other key market strategies and a relevant patent analysis
- Profiles of the leading companies, including Gilead Sciences Inc., GSK plc., Sanofi, Merck & Co. Inc., and Abbott
Table of Contents
Chapter 1 Executive Summary
- Market Outlook
- Scope of Report
- Market Summary
- Market Dynamics
- Emerging Trends
- Analysis by Segment
- Analysis by Region
- Conclusion
Chapter 2 Market Overview
- Infectious Diseases
- Management of Infectious Diseases
- Antimicrobial Resistance
- Disease Overviews
- Human Immunodeficiency Virus
- Influenza
- Hepatitis
- Respiratory Syncytial Virus
- Tuberculosis
- Herpes Simplex Virus
- Malaria
- Rotavirus
- Viral Hemorrhagic Fevers-Yellow Fever
- Viral Hemorrhagic Fevers-Dengue
- Viral Hemorrhagic Fevers-Lassa Fever
- Viral Hemorrhagic Fevers-Ebola Fever
- Viral Hemorrhagic Fevers-Zika Virus
- Analysis of Macroeconomic Factors
- Impact of U.S. Tariffs on the Pharmaceutical Industry
- Global Economic Growth
- Demographic Trends
- Porter's Five Forces Analysis
- Bargaining Power of Buyers (Moderate to High)
- Bargaining Power of Suppliers (Moderate to Low)
- Threat of New Entrants (Moderate to Low)
- Threat of Substitutes (Low)
- Level of Competitiveness (High)
Chapter 3 Market Dynamics
- Market Dynamics
- Market Drivers
- Resistance to Drugs
- Global Efforts to Combat Infectious Diseases
- Technological Advances
- Climate Change
- International Travel
- Market Restraints
- Loss of Exclusivity and Genericization
- Pricing Pressures
- Lack of Awareness and Underdiagnosis
- Market Trends
- Long-acting Injectable Medicines
- Self-Testing Kits
Chapter 4 Regulatory Landscape
- Regulatory Aspects
- U.S.
- European Union
- Japan
- Regulatory Aspects of Infectious Disease Diagnostics
- U.S.
- EU
- Japan
Chapter 5 Emerging Technologies and Developments
- Emerging Technologies
- Multiplex PCR Syndromic Testing
- NGS and Genetic Medicine
- Pipeline Analysis
- Takeaways
- Novel Therapeutic Agents in Phase 3 Development
Chapter 6 Market Segmentation Analysis
- Segmentation Breakdown
- Global Infectious Disease Treatment Market, by Product
- Therapeutics
- Vaccines
- Diagnostics
- Global Infectious Disease Treatment Market, by Disease
- HIV/AIDS
- Influenza
- Hepatitis B
- Hepatitis C
- Respiratory Syncytial Virus
- Tuberculosis
- Herpes Simplex Virus
- Malaria
- Rotavirus
- Viral Hemorrhagic Fevers
- Geographic Breakdown
- Global Infectious Disease Treatment Market, by Region
- North America
- Europe
- Asia-Pacific
- Middle East and Africa (MEA)
- South America
Chapter 7 Competitive Intelligence
- Overview
- Infectious Disease Therapeutics Market Shares
- Infectious Disease Vaccines Market Share Analysis
- Infectious Disease Diagnostics Market Ranking
Chapter 8 Sustainability in Infectious Disease Treatment Industry: An ESG Perspective
- Introduction to ESG
- ESG Issues Specific to the Infectious Disease Treatment Market
- Global Health Access and Equity
- R&D for Neglected and Emerging Infectious Diseases
- Antimicrobial Stewardship
- Collaborations with Public Health Bodies
- Concluding Remarks
Chapter 9 Appendix
- Methodology
- Sources
- Abbreviations
- Company Profiles
- ABBOTT
- ABBVIE INC.
- CSL
- DANAHER CORP.
- F. HOFFMANN-LA ROCHE LTD.
- GILEAD SCIENCES INC.
- GSK PLC
- JOHNSON & JOHNSON SERVICES INC.
- MERCK & CO. INC.
- MOLBIO DIAGNOSTICS LTD.
- ORASURE TECHNOLOGIES INC.
- PFIZER INC.
- SANOFI
- SERUM INSTITUTE OF INDIA PVT. LTD.
- SIEMENS HEATHINEERS AG
- Emerging Start-ups/Market Disruptors
